Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ANKRD35 divergent transcript (ANKRD35-DT) is annotated as a long non-coding RNA gene. lncRNAs such as ANKRD35-DT are DNA regions transcribed into RNA but not translated into proteins. "Divergent transcript" refers to the phenomenon where transcription occurs in opposite directions from a promoter, generating both a protein-coding transcript (e.g., ANKRD35 proper) and a non-coding transcript (ANKRD35-DT)[1]. Most divergent transcripts are unstable and of unknown functional relevance, but some lncRNAs regulate gene expression or chromatin structure[1][5]. There is no evidence that ANKRD35-DT is a protein-coding gene, nor that it functions as a classical pharmacological target (receptor, enzyme, etc.). Its specific molecular function, disease involvement, and pharmaceutical relevance have not been established[5].
None reported
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ANKRD35 divergent transcript (ANKRD35-DT).